The first treatment being tested is LY-CoV555, an investigational antibody developed from the blood sample of a recovered COVID-19 patient. LY-CoV555 is delivered via intravenous infusion.
In this Clinical OMICs webinar, sponsored by Owkin, a distinguished panel of breast cancer experts and machine learning researchers, including world-renowned expert Dr. Fabrice André, will explore how clinicians and data scientists can collaborate to accelerate research through the application of novel computational and federated learning techniques.
The collaboration with the CDC and the JRC will develop a novel process for standardizing SARS-CoV-2 assays by anchoring each protein to a neutralization antibody titer—a level of antibody present to block virus from entering cells in laboratory experiments.
Under the agreement, Covance will join Tempus’ TIME Trial Network, a data-driven approach that aims to improve the efficiency of clinical trials recruitment, design, and launch.
The study will support research on health disparities in brain aging and Alzheimer’s between Mexican Americans and non-Latino whites. It is believed that Hispanics are approximately one and one-half times more likely to have Alzheimer’s or other dementias as older whites.
In this Clinical OMICs KEYNOTE webinar, sponsored by Illumina, we are delighted to host two true pioneers of clinical genome sequencing, bioinformatician Dr. Liz Worthey and geneticist Dr. Howard Jacob, who will reflect on a decade of progress in clinical genome analysis and discuss the future challenges confronting the field.
AstraZeneca and the University of Oxford resumed the clinical study they paused last week after one U.K. participant developed a “potentially unexplained illness,” while Pfizer and BioNTech have requested FDA approval to add 14,000 participants to their late-stage study.
Neutrophil extracellular traps (NETs) often appeared to almost completely obstruct the small bronchioles and alveoli that mediate gas exchange.
As well as finding a number of genetic variants also found in other cancers, the researchers discovered three variants specific to patients with the more aggressive cancer, notably, they also identified an inhibitor that could target one of the genetic mutations specific to adenosquamous pancreatic cancer.
There is a need for a quicker and more efficient antibody tests that can detect levels of antibodies against COVID-19, both so that prior infection and levels of immunity can be detected, but also to test plasma being used as a therapy.